Skip to main content
Top
Published in: Journal of Translational Medicine 1/2021

Open Access 01-12-2021 | Heart Failure | Research

Multi-trajectories of lipid indices with incident cardiovascular disease, heart failure, and all-cause mortality: 23 years follow-up of two US cohort studies

Authors: Fatemeh Koohi, Davood Khalili, Mohammad Ali Mansournia, Farzad Hadaegh, Hamid Soori

Published in: Journal of Translational Medicine | Issue 1/2021

Login to get access

Abstract

Background

Understanding the distinct patterns (trajectories) of variation in blood lipid levels before diagnosing cardiovascular disease (CVD) might carry important implications for improving disease prevention or treatment.

Methods

We investigated 14,373 participants (45.5% men) aged 45–84 from two large US prospective cohort studies with a median of 23 years follow-up. First, we jointly estimated developmental trajectories of lipid indices, including low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglyceride (TG) concentrations using group-based multi-trajectory modeling. Then, the association of identified multi-trajectories with incident CVD, heart failure, and all-cause mortality were examined using Cox proportional hazard model.

Results

Seven distinct multi-trajectories were identified. The majority of participants (approximately 80%) exhibited decreasing LDL-C but rising TG levels and relatively stable HDL-C levels. Compared to the individuals with healthy and stable LDL-C, HDL-C, and TG levels, those in other groups were at significant risk of incident CVD after adjusting for other conventional risk factors. Individuals with the highest but decreasing LDL-C and borderline high and rising TG levels over time were at the highest risk than those in other groups with a 2.22-fold risk of CVD. Also, those with the highest and increased triglyceride levels over time, over optimal and decreasing LDL-C levels, and the lowest HDL-C profile had a nearly 1.84 times CVD risk. Even individuals in the multi-trajectory group with the highest HDL-C, optimal LDL-C, and optimal TG levels had a significant risk (HR, 1.45; 95% CI 1.02–2.08). Furthermore, only those with the highest HDL-C profile increased the risk of heart failure by 1.5-fold (95% CI 1.07–2.06).

Conclusions

The trajectories and risk of CVD identified in this study demonstrated that despite a decline in LDL-C over time, a significant amount of residual risk for CVD remains. These findings suggest the impact of the increasing trend of TG on CVD risk and emphasize the importance of assessing the lipid levels at each visit and undertaking potential interventions that lower triglyceride concentrations to reduce the residual risk of CVD, even among those with the optimal LDL-C level.
Appendix
Available only for authorised users
Literature
26.
go back to reference Johnson CL, et al. Declining serum total cholesterol levels among US adults. The national health and nutrition examination surveys. JAMA. 1993;269:3002–8.CrossRef Johnson CL, et al. Declining serum total cholesterol levels among US adults. The national health and nutrition examination surveys. JAMA. 1993;269:3002–8.CrossRef
27.
go back to reference Ganda OP, Bhatt DL, Mason RP, Miller M, Boden WE. Unmet need for adjunctive dyslipidemia therapy in hypertriglyceridemia management. J Am Coll Cardiol. 2018;72:330–43.CrossRef Ganda OP, Bhatt DL, Mason RP, Miller M, Boden WE. Unmet need for adjunctive dyslipidemia therapy in hypertriglyceridemia management. J Am Coll Cardiol. 2018;72:330–43.CrossRef
28.
go back to reference Nejat A, et al. Changes in lipid measures and incident coronary heart disease: Tehran lipid & glucose study. Clin Biochem. 2014;47:1239–44.CrossRef Nejat A, et al. Changes in lipid measures and incident coronary heart disease: Tehran lipid & glucose study. Clin Biochem. 2014;47:1239–44.CrossRef
29.
go back to reference Nordestgaard BG, Benn M, Schnohr P, Tybjærg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007;298:299–308.CrossRef Nordestgaard BG, Benn M, Schnohr P, Tybjærg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007;298:299–308.CrossRef
30.
go back to reference Sarvar R, Danesh J, Eriksdottir J. Triglycerides and the risk of heart disease. 10 158 incident cases among 262 525 participants in 29 western population studies. Circulation. 2007;115:450–8.CrossRef Sarvar R, Danesh J, Eriksdottir J. Triglycerides and the risk of heart disease. 10 158 incident cases among 262 525 participants in 29 western population studies. Circulation. 2007;115:450–8.CrossRef
31.
go back to reference Varbo A, et al. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol. 2013;61:427–36.CrossRef Varbo A, et al. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol. 2013;61:427–36.CrossRef
32.
go back to reference Consortium TCDG, Collaboration ERF. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet. 2010;375:1634–9.CrossRef Consortium TCDG, Collaboration ERF. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet. 2010;375:1634–9.CrossRef
34.
go back to reference Aberra T, et al. The association between triglycerides and incident cardiovascular disease: what is “optimal”? J Clin Lipidol. 2020;14:438–47.CrossRef Aberra T, et al. The association between triglycerides and incident cardiovascular disease: what is “optimal”? J Clin Lipidol. 2020;14:438–47.CrossRef
35.
go back to reference Lawler PR, et al. Real-world risk of cardiovascular outcomes associated with hypertriglyceridaemia among individuals with atherosclerotic cardiovascular disease and potential eligibility for emerging therapies. Eur Heart J. 2020;41:86–94.CrossRef Lawler PR, et al. Real-world risk of cardiovascular outcomes associated with hypertriglyceridaemia among individuals with atherosclerotic cardiovascular disease and potential eligibility for emerging therapies. Eur Heart J. 2020;41:86–94.CrossRef
36.
go back to reference Kajikawa M, et al. Target of triglycerides as residual risk for cardiovascular events in patients with coronary artery disease—post hoc analysis of the FMD-J study A. Circ J. 2019;83:1064–71.CrossRef Kajikawa M, et al. Target of triglycerides as residual risk for cardiovascular events in patients with coronary artery disease—post hoc analysis of the FMD-J study A. Circ J. 2019;83:1064–71.CrossRef
37.
go back to reference Miller M, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011;123:2292–333.CrossRef Miller M, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011;123:2292–333.CrossRef
38.
go back to reference Nordestgaard B, Langsted A, Freiberg J. Nonfasting hyperlipidemia and cardiovascular disease. Curr Drug Targets. 2009;10:328–35.CrossRef Nordestgaard B, Langsted A, Freiberg J. Nonfasting hyperlipidemia and cardiovascular disease. Curr Drug Targets. 2009;10:328–35.CrossRef
43.
go back to reference Ference BA, et al. Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease. JAMA. 2019;321:364–73.CrossRef Ference BA, et al. Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease. JAMA. 2019;321:364–73.CrossRef
44.
go back to reference Chapman MJ, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J. 2011;32:1345–61.CrossRef Chapman MJ, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J. 2011;32:1345–61.CrossRef
46.
go back to reference Simes RJ, et al. Relationship between lipid levels and clinical outcomes in the long-term intervention with pravastatin in ischemic disease (LIPID) trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels? Circulation. 2002;105:1162–9. https://doi.org/10.1161/hc1002.105136.CrossRefPubMed Simes RJ, et al. Relationship between lipid levels and clinical outcomes in the long-term intervention with pravastatin in ischemic disease (LIPID) trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels? Circulation. 2002;105:1162–9. https://​doi.​org/​10.​1161/​hc1002.​105136.CrossRefPubMed
47.
go back to reference Miller M, et al. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2008;51:724–30.CrossRef Miller M, et al. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2008;51:724–30.CrossRef
48.
go back to reference Bhatt DL, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380:11–22.CrossRef Bhatt DL, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380:11–22.CrossRef
49.
go back to reference Marston NA, et al. Association between triglyceride lowering and reduction of cardiovascular risk across multiple lipid-lowering therapeutic classes: a systematic review and meta-regression analysis of randomized controlled trials. Circulation. 2019;140:1308–17.CrossRef Marston NA, et al. Association between triglyceride lowering and reduction of cardiovascular risk across multiple lipid-lowering therapeutic classes: a systematic review and meta-regression analysis of randomized controlled trials. Circulation. 2019;140:1308–17.CrossRef
58.
go back to reference Bollen KA, Curran PJ. Latent curve models: a structural equation perspective. Hoboken: Wiley; 2006. Bollen KA, Curran PJ. Latent curve models: a structural equation perspective. Hoboken: Wiley; 2006.
Metadata
Title
Multi-trajectories of lipid indices with incident cardiovascular disease, heart failure, and all-cause mortality: 23 years follow-up of two US cohort studies
Authors
Fatemeh Koohi
Davood Khalili
Mohammad Ali Mansournia
Farzad Hadaegh
Hamid Soori
Publication date
01-12-2021
Publisher
BioMed Central
Keyword
Heart Failure
Published in
Journal of Translational Medicine / Issue 1/2021
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-021-02966-4

Other articles of this Issue 1/2021

Journal of Translational Medicine 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.